1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
AVITA Medical, Inc.

AVITA Medical, Inc.

AVHHL
AVITA Medical, Inc.US flagOther OTC
0.85
USD
- -
- -
104.96MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.15
0.14
0.11
0.03
0.02
0.02
0.09
0.14
0.26
0.28
0.4
0.5
- -
0.5
Basic EPS, GAAP
-0.43
-0.26
-0.27
-0.21
-0.24
-0.27
-0.4
-0.41
-0.23
-0.21
-0.28
-0.48
- -
-0.31
Free Cash Flow per Basic Share
-0.43
-0.38
-0.32
-0.21
-0.18
-0.28
-0.32
-0.23
-0.24
-0.16
-0.31
-0.45
- -
-0.22
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.4
0.25
0.14
0.14
0.05
0.22
-2.41
-1.92
-1.95
-2.1
-2.35
-2.78
- -
-2.9
Tangible Book Value per Share
0.56
0.28
0.16
0.18
0.11
0.3
0.33
0.71
1.02
0.67
0.38
-0.01
- -
-0.2
Basic Weighted Avg Shares
17
18
20
28
37
47
63
101
113
125
127
129
- -
145
Sales/Revenue/Turnover
3
3
2
1
1
1
5
14
29
34
50
64
72
72
Operating Margin (%)
-335.99
-269.39
-290.53
-1,134.12
-1,430.17
-1,489.88
-466.35
-299.23
-90.79
-79.91
-85.07
-88.08
-59.4
-54.62
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
2
2
Net Income, GAAP
-7
-5
-5
-6
-9
-13
-25
-42
-27
-27
-35
-62
-49
-45
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-287.49
-191.84
-258.44
-776.24
-1,277.05
-1,370.83
-458.57
-294.68
-90.94
-77.47
-70.56
-96.26
-67.85
-62.67
Working Capital
9
5
3
5
4
14
20
71
114
77
91
37
-27
-35
LT Debt
- -
- -
- -
- -
- -
- -
- -
2
1
- -
42
45
2
2
Total Equity
10
5
3
5
4
14
21
72
116
85
49
4
-17
-23
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-124.03
-85.3
-149.2
-175.98
-302.99
-204.98
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
42
44
46
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
31
31
Market Capitalization
253
149
168

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
41
35
32
Cash, Cash Equivalents & STI
23
18
14
Accounts Receivable, Net
9
9
10
Inventories
7
7
6
Total Current Liabilities
62
63
67
Payables & Accruals
14
17
15
ST Debt
42
44
46
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.65%
-114%
-470.08%
Free Cash Flow
26.17%
18.29%
-44.57%
Net Income, GAAP
31.7%
9.92%
-21.44%
Sales/Revenue/Turnover
81.99%
41.59%
11.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11
15
20
18
64
2025
19
18
17
18
72
2026
19
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.15
-0.12
-0.12
-0.09
-0.48
2025
-0.11
-0.08
-0.09
-0.08
- -
2026
-0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Cary G. Vance
Full Time Employees
260
Sector
Healthcare
Industry
Medical - Devices
Address
28159 Avenue Stanford Valencia CA United States of America 91355
IPO Date
Sep 4, 2003
CIK
0001762303
Website
avitamedical.com
Similar Companies
Gaush Meditech Ltd (2407.HK)
Viemed Healthcare, Inc. (VMD.TO)
Abbott Laboratories (ABL.DE)
Adiuvo Investments S.A. (ADV.WA)
TransMedics Group, Inc. (TMDX)
Delcath Systems, Inc. (DCTH)
Business
AVITA Medical, Inc. (Ticker: AVHHL) develops and commercializes regenerative medicine technologies focused on therapeutic acute wound care, optimizing wound healing and accelerating patient recovery for burns, chronic wounds, trauma, surgical defects, and skin restoration applications. The company offers the RECELL System, an FDA-approved point-of-care platform that processes a patient's own skin to produce Spray-On Skin Cells for treating thermal burn wounds and full-thickness skin defects; RECELL GO System and RECELL GO mini, next-generation devices approved by the FDA in June and December 2024, respectively, for enhanced treatment efficiency including smaller wounds; PermeaDerm, a biosynthetic transparent wound matrix to which AVITA holds exclusive U.S. marketing, sales, and distribution rights; and Cohealyx, a collagen-based dermal matrix cleared by the FDA in December 2024 and co-developed with Regenity Biosciences for full-thickness wound management. AVITA Medical serves hospitals, treatment centers, and distributors primarily in the United States, Europe, and Asia-Pacific. Founded in 1993 and headquartered in Valencia, California, the company, formerly known as AVITA Therapeutics, Inc., rebranded to AVITA Medical, Inc. to reflect its commercial-stage focus on wound care solutions. In the last two years, AVITA Medical achieved approximately 29% revenue growth in 2024 over the prior year, driven by expanded adoption of its product portfolio; launched the RECELL GO System and RECELL GO mini following FDA approvals to broaden applications in new and existing accounts; introduced Cohealyx to strengthen its dermal matrix offerings; completed an Australian equity raise of about US$15 million in August 2025 to fund growth initiatives and operations into 2026; and revised its full-year 2025 revenue guidance to $70-74 million amid claims processing challenges while reaffirming its long-term trajectory targeting a $3.5 billion total addressable market.

Company News

APIChat

  • seekingalpha.com

    AVITA Medical, Inc. (RCEL) Q1 2026 Earnings Call Transcript